Qais Radaideh
Cardiovascular Disease · Omaha, NENPI 1063829844
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (59.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 65.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $37,818, more than ten times the $88 reported in 2019. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $259.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$33K
- Abbott$6K
- Boston Scientific$5K
- Edwards Lifesciences$3K
- Amgen$509
- Shockwave Medical, Inc$506
- plus $2K from 12 others
What the payments were for
- Grants$29,45559%
- Travel & lodging$9,05618%
- Food & beverage$10,02720%
- Education$1,1892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 46 | $32,743 |
| Abbott | 39 | $5,731 |
| Boston Scientific | 33 | $5,354 |
| Edwards Lifesciences | 32 | $2,928 |
| Amgen | 5 | $509 |
| Shockwave Medical, Inc | 11 | $506 |
| Johnson & Johnson | 4 | $295 |
| Astellas Pharma US Inc | 3 | $268 |
| Bard Peripheral Vascular, Inc. | 1 | $263 |
| AstraZeneca | 2 | $248 |
| Abiomed | 3 | $178 |
| Surmodics, Inc. | 1 | $155 |
| Angiodynamics, Inc. | 2 | $152 |
| Teleflex LLC | 2 | $144 |
| Novartis | 3 | $134 |
| Pfizer | 3 | $76 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$2,032
- ONYX FRONTIER$1,840
- MitraClip$1,549
- GENERAL - THERAPIES$1,346
- COREVALVE EVOLUT R$1,320
- SAPIEN 3 Ultra RESILIA$722
- PASCAL$643
- Repatha$493
- VersaCross Access Solution$355
- Pounce Thrombectomy System$309
- RotarexS 6 F x 135 cm$263
- XARELTO$239
- GENERAL VASCULAR ACCESS$235
- EnSite Precision Cardiac Mapping System$210
- Rotablator Rotational Atherectomy System Console Kit$181
- ESPRIT$166
- ENSITE$161
- TRICLIP$160
- CONCERTOTM$156
- ENSITE PRECISION$150
How this compares
$49,728 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $27,158 |
| BrilintaTicagrelor | 18 | $12,412 |
| JardianceEmpagliflozin | 11 | $10,529 |
| ClopidogrelClopidogrel Bisulfate | 48 | $650 |
| Atorvastatin Calcium | 32 | $226 |
| Rosuvastatin Calcium | 15 | $131 |
| Losartan Potassium | 14 | $127 |
| Metoprolol Succinate | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $27,15822 claims |
| AstraZenecaBrilinta | $248 | $12,41218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
- Shiva PonamgiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.